GlassScriptPhysician profile
Donald Gary Soya
NPI 1932175981
$1,533.64
in general payments reported to CMS, 2019-2025
17 companies · $336 in 2025
The $336 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66.37 · 2020: $54.70 · 2021: $95.28 · 2022: $138 · 2023: $381 · 2024: $462 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $314.83 | 2022-2025 | |
| Boston Scientific Corporation | $231.00 | 2023-2025 | Watchman Flx, Avvigo Guidance System |
| Astrazeneca Pharmaceuticals LP | $164.07 | 2021-2024 | Farxiga |
| Pfizer INC. | $125.55 | 2020-2025 | |
| Abbott Laboratories | $113.78 | 2019-2025 | Agilis, Xience Skypoint |
| Novo Nordisk INC | $104.86 | 2024-2025 | Wegovy, Ozempic |
| Amgen INC. | $103.77 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $75.20 | 2022-2025 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $60.05 | 2023-2024 | Inpefa |
| Astellas Pharma US INC | $48.11 | 2022 | |
| Ge Healthcare | $42.91 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $41.38 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $39.34 | 2020-2024 | Xarelto |
| Medtronic, INC. | $22.24 | 2025 | Reveal Linq |
| Alnylam Pharmaceuticals INC. | $18.00 | 2025 | Amvuttra |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $15.19 | 2025 | Carto 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.36 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Soya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.